Abstract
PRIN-UNO focuses on the design and early-stage development of innovative Pin1 inhibitors, targeting a key enzyme involved in tumor growth, progression, and resistance to therapy. Starting from two chemotype series, the project combines structure-based drug design, biochemical screening, and preclinical evaluation in 2D cultures and 3D cancer models. A key component is the analytical profiling of candidate molecules, with in-depth assessment of their metabolic fate, bioavailability, and pharmacokinetic properties. This is achieved through original miniaturized sampling and mass spectrometry-based workflows, designed to ensure high sensitivity and reliability from limited sample volumes. These analytical strategies support the identification of drug-like compounds with favorable ADME-Tox profiles and guide their selection for in vivo testing. The ultimate goal is to deliver one or more validated lead compounds suitable for future development as targeted anticancer therapeutics.
Project details
Unibo Team Leader: Michele Protti
Unibo involved Department/s:
Dipartimento di Farmacia e Biotecnologie
Coordinator:
Università degli Studi di TORINO(Italy)
Total Unibo Contribution: Euro (EUR) 58.514,00
Project Duration in months: 24
Start Date:
30/11/2023
End Date:
28/02/2026
